Insights

Public Benefit Focus As a Public Benefit Corporation with a mission to address global snakebite envenomation, Ophirex presents opportunities to partner with government health programs, NGOs, and public health initiatives seeking accessible, urgently deployable treatments for high-need regions.

Defense & DHAP Ties With funding and backing from the Defense Health Agency and DoD-backed programs, there is a clear path for defense contracting and military medical logistic collaborations to scale development, trials, and potential adoption in field kits.

Strategic Partnerships Recent collaborations to produce marimastat for LSTM and ongoing development of varespladib indicate a strategy of diversified venom-targeted modalities, suggesting opportunities to pair with contract manufacturing, CROs, and university research alliances to accelerate clinical milestones.

Global Market Need Large global snakebite burden with significant pre-hospital mortality underscores demand for an oral rescue therapy; sales opportunities exist with emergency medical services, telemedicine platforms, veterinary markets, and regional distributors in high-incidence regions.

Scale & Readiness Current revenue and funding levels, combined with a growing clinical pipeline and a relatively lean team, point to a need for scalable manufacturing, logistics, and regulatory support partners to prepare for Phase 2 trials and potential broader commercialization.

Similar companies to Ophirex, Inc.

Ophirex, Inc. Tech Stack

Ophirex, Inc. uses 8 technology products and services including Amazon Web Services, Squarespace, WordPress, and more. Explore Ophirex, Inc.'s tech stack below.

Media & News

Ophirex, Inc.'s Email Address Formats

Ophirex, Inc. uses at least 1 email format:
Ophirex, Inc. Email FormatsExamplePercentage
First@ophirex.comJohn@ophirex.com
100%

Frequently Asked Questions

What is Ophirex, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Ophirex, Inc.'s official website is ophirex.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Ophirex, Inc. generate?

Minus sign iconPlus sign icon
As of October 2026, Ophirex, Inc.'s annual revenue is estimated to be $10M - $25M.

What is Ophirex, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Ophirex, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ophirex, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2026, Ophirex, Inc. has approximately 27 employees across 1 continents, including North America. Key team members include Chief Executive Officer: J. G., Senior Vice President Regulatory Affairs: J. H. and Vice President: R. C. Explore Ophirex, Inc.'s employee directory with LeadIQ.

What industry does Ophirex, Inc. belong to?

Minus sign iconPlus sign icon
Ophirex, Inc. operates in the Biotechnology Research industry.

What technology does Ophirex, Inc. use?

Minus sign iconPlus sign icon
Ophirex, Inc.'s tech stack includes Amazon Web Services, Squarespace, WordPress, CookieYes, Squarespace Commerce, Cornerstone, Webflow and WP Engine.

What is Ophirex, Inc.'s email format?

Minus sign iconPlus sign icon
Ophirex, Inc.'s email format typically follows the pattern of First@ophirex.com. Find more Ophirex, Inc. email formats with LeadIQ.

How much funding has Ophirex, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2026, Ophirex, Inc. has raised $53M in funding. The last funding round occurred on Jan 05, 2023 for $37M.

When was Ophirex, Inc. founded?

Minus sign iconPlus sign icon
Ophirex, Inc. was founded in 2015.
Ophirex, Inc. logo

Ophirex, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Ophirex, Inc. is a Public Benefit Corporation in the biotechnology research space, headquartered in Corte Madera, California. It is developing varespladib, an oral rescue therapy intended to be administered at the moment of a snakebite to rapidly counteract venom effects. Varespladib inhibits secretory phospholipase A2, a toxin common to the vast majority of venomous snakes, with development for use in both humans and dogs.

The company operates within the snakebite envenomation field, aiming to change the treatment approach by enabling early self-administration. Global snakebite figures point to 4–5 million bites annually, roughly 125,000 deaths, and about 400,000 permanent disabilities, with about 75% of deaths occurring before hospital arrival; in the United States, around 50,000 dogs are bitten by venomous snakes each year. In February 2026, Ophirex signed a new client and announced an agreement to produce marimastat for the Liverpool School of Tropical Medicine, reflecting ongoing expansion of its partnerships.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $53M

    Ophirex, Inc. has raised a total of $53M of funding over 2 rounds. Their latest funding round was raised on Jan 05, 2023 in the amount of $37M as a Series B.

  • $10M - $25M

    Ophirex, Inc.'s revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.